Durect
- Country
- Ownership
- -
- Employees
- 58
- Market Cap
- -
- Introduction
DURECT Corp. focuses on advancing novel and potentially lifesaving investigational therapies derived from its Epigenetic Regulator Program. Its pipeline is called DUR-928, an endogenous sulfated oxysterol and an epigenetic regulator. The company was founded by James E. Brown and Felix Theeuwes on February 6, 1998 and is headquartered in Cupertino, CA.
An International Trial to Evaluate the Efficacy and Safety of SABER®-Bupivacaine for Postoperative Pain Control in Patients Undergoing Hysterectomy
- First Posted Date
- 2009-10-12
- Last Posted Date
- 2021-06-01
- Lead Sponsor
- Durect
- Target Recruit Count
- 115
- Registration Number
- NCT00993226
- Locations
- 🇬🇧
Nycomed, London, United Kingdom
A Safety and Efficacy Study of SABER®-Bupivacaine for Pain Following Hernia Repair
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-09-10
- Last Posted Date
- 2021-05-27
- Lead Sponsor
- Durect
- Target Recruit Count
- 124
- Registration Number
- NCT00974350
A Safety and Effectiveness Study of SABER®-Bupivacaine for Pain Following Shoulder Surgery
- First Posted Date
- 2009-01-07
- Last Posted Date
- 2021-06-01
- Lead Sponsor
- Durect
- Target Recruit Count
- 60
- Registration Number
- NCT00818363
Open Label, Safety Study of EN3270 in Patients With Moderate to Severe Non-malignant, Chronic Pain
- First Posted Date
- 2007-06-12
- Last Posted Date
- 2012-02-23
- Lead Sponsor
- Durect
- Target Recruit Count
- 77
- Registration Number
- NCT00485225
- Locations
- 🇺🇸
Comprehensive Clinical Research, Berlin, New Jersey, United States
Study of a Bupivacaine Patch (Eladur™) to Treat Post- Herpetic Neuralgia
Phase 2
Completed
- Conditions
- First Posted Date
- 2007-05-24
- Last Posted Date
- 2009-09-11
- Lead Sponsor
- Durect
- Target Recruit Count
- 60
- Registration Number
- NCT00478179
© Copyright 2024. All Rights Reserved by MedPath